| 0.7616 0 (0%) | 03-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.16 | 1-year : | 1.44 |
| Resists | First : | 0.99 | Second : | 1.23 |
| Pivot price | 0.79  |
|||
| Supports | First : | 0.6 | Second : | 0.5 |
| MAs | MA(5) : | 0.76 | MA(20) : | 0.85 |
| MA(100) : | 1.22 |
MA(250) : | 1.89 |
|
| MACD | MACD : | -0.1  |
Signal : | -0.2 |
| %K %D | K(14,3) : | 32.1 |
D(3) : | 30 |
| RSI | RSI(14): 35.1 | |||
| 52-week | High : | 4 | Low : | 0.6 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ISO ] has closed above bottom band by 35.8%. Bollinger Bands are 64.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.76 - 0.77 | 0.77 - 0.77 |
| Low: | 0.75 - 0.76 | 0.76 - 0.76 |
| Close: | 0.75 - 0.76 | 0.76 - 0.77 |
IsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States, Canada, the United Kingdom, Belgium, France, the Czech Republic, Spain, Germany, Sweden, Italy, Israel, Switzerland, China and Taiwan, Singapore, Japan, Australia, and Korea. The company offers single cell proteomics platform, including instruments, chip consumables, and software that provides an end-to-end solution to view of protein function at an individual cellular level. It provides IsoLight and IsoSpark instruments; IsoCode chips that offer multiplexed chip solutions for single cell functional proteomics; CodePlex chips that provide multiplexed solutions for ultra-low volume bulk samples; and IsoSpeak software that offers dimensional data and automates analysis with an intuitive push button user interface to deliver same day single cell and bulk proteome visualizations, as well as research support and services, and post-warranty services. The company was incorporated in 2013 and is based in Branford, Connecticut.
Tue, 21 Mar 2023
Berkeley Lights Completes Acquisition of IsoPlexis Forming PhenomeX, the Functional Cell Biology Company - PR Newswire
Tue, 03 Jan 2023
Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company - News-Medical.Net
Wed, 21 Dec 2022
Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company - GlobeNewswire
Tue, 23 Aug 2022
IsoPlexis Appoints Nachum “Homi” Shamir to its Board of Directors - citybiz
Fri, 08 Apr 2022
IsoPlexis to Present First-of-Its-Kind Data on Simultaneous Single Cell TCR Profiling and Highly Multiplexed Functional ... - GlobeNewswire
Wed, 20 Oct 2021
IsoPlexis Nets $111M from IPO to Expand Platform, Product Offerings, Distribution Network - Genetic Engineering & Biotechnology News
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 40 (M) |
| Shares Float | 18 (M) |
| Held by Insiders | 15.5 (%) |
| Held by Institutions | 76.9 (%) |
| Shares Short | 116 (K) |
| Shares Short P.Month | 242 (K) |
| EPS | -2.55 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.03 |
| Profit Margin | 0 % |
| Operating Margin | -578.7 % |
| Return on Assets (ttm) | -40.9 % |
| Return on Equity (ttm) | -115.6 % |
| Qtrly Rev. Growth | -39.5 % |
| Gross Profit (p.s.) | -0.03 |
| Sales Per Share | 0.42 |
| EBITDA (p.s.) | -2.36 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -97 (M) |
| Levered Free Cash Flow | -61 (M) |
| PE Ratio | -0.3 |
| PEG Ratio | 0 |
| Price to Book value | 0.73 |
| Price to Sales | 1.8 |
| Price to Cash Flow | -0.32 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|